# Avastin and Taxotere for Esophagogastric Cancer

> **NCT00137813** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 42 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00137813
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-09
- **Final completion:** 2009-09
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-11-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137813, "Avastin and Taxotere for Esophagogastric Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00137813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*